Taysha Gene Therapies Inc... (TSHA)
Company Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system.
It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments.
The company was incorporated in 2019 and is based in Dallas, Texas.

Country | United States |
IPO Date | Sep 24, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 73 |
CEO | Sean P. Nolan |
Contact Details
Address: 3000 Pegasus Park Drive Dallas, Texas United States | |
Website | https://www.tayshagtx.com |
Stock Details
Ticker Symbol | TSHA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001806310 |
CUSIP Number | 877619106 |
ISIN Number | US8776191061 |
Employer ID | 84-3199512 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Sean P. Nolan | Chief Executive Officer & Chairman |
Kamran Alam CPA, M.B.A. | Chief Financial Officer & Corporate Secretary |
Tracy M. Porter SPHR | Chief People Officer |
Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program |
Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program |
Dr. Sukumar Nagendran M.D. | President, Head of Research & Development and Director |
Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer |
Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer |
Hayleigh Collins | Director of Corporate Communications & Investor Relations |
Sean McAuliffe | Chief Business Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 03, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Jun 03, 2025 | 4 | Filing |
Jun 03, 2025 | 8-K | Current Report |
May 29, 2025 | 8-K | Current Report |
May 29, 2025 | 424B5 | Filing |
May 29, 2025 | 8-K/A | [Amend] Current Report |
May 28, 2025 | 424B5 | Filing |
May 28, 2025 | 8-K | Current Report |
May 15, 2025 | 10-Q | Quarterly Report |
May 15, 2025 | 8-K | Current Report |